Full video transcriptClick to expand
Auto-generated transcript of @anthonypacellaa's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Steroids should not be relied upon for weight loss guys. I've been saying this from the very beginning steroids are something that you can fine-tune and
- 0:06Polish and get more dense and build more muscle but to actually rely on steroids for weight loss is not what you want to do.
- 0:12If you have the balls to take T3 and clean which are not steroids, that's great and that's going to get you really shredded if you know how to use them.
- 0:18However peptides guys are the new but really truly proven thing. I look at peptides as the crypto market except crypto is not proven.
- 0:26I don't really believe in crypto anymore. I don't think we're going to ever have a time and day where we're going to be able to use crypto to pay for whatever we want.
- 0:33I feel like it would have already been here by now and I know peptides is like apples and oranges but it's hit the mainstream and it's actually really proven.
- 0:40We're seeing great studies on it. We're seeing great reports on it. I'm using it a lot. Everybody's trying to create a peptide company including me and my partner.
- 0:48You can DM me to get peptides AOD, CJC, I have a Morelen, Mott C, all this good stuff for weight loss.
- 0:55If you're having ED problems, chrzepatide or some aglutide, all that shit guys.
Peptide 'gains and fat loss' claims on TikTok: what the data says
Quick answer
The video promotes a stack of fat-loss peptides including AOD-9604, CJC-1295, and Ipamorelin alongside GLP-1 receptor agonists like semaglutide and tirzepatide, while also endorsing Clenbuterol and T3 for body composition. Several of these compounds carry meaningful cardiovascular and endocrine risks, and none of the peptides mentioned have FDA approval for fat loss in healthy adults. The suggestion that semaglutide or tirzepatide address erectile dysfunction reflects a mischaracterization of their approved indications and mechanism of action.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptide 'gains and fat loss' claims on TikTok: what the data says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Peptide 'gains and fat loss' claims on TikTok: what the data says should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Peptide 'gains and fat loss' claims on TikTok: what the data says" from Anthony Pacella. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video promotes a stack of fat-loss peptides including AOD-9604, CJC-1295, and Ipamorelin alongside GLP-1 receptor agonists like semaglutide and tirzepatide, while also endorsing Clenbuterol and T3 for body composition.
The reason this review is not generic is the source wording and the canonical claim label "peptides research purposes only dm for more info this tik tok does no." In this clip, the useful excerpt is: "Steroids should not be relied upon for weight loss guys." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video promotes a stack of fat-loss peptides including AOD-9604, CJC-1295, and Ipamorelin alongside GLP-1 receptor agonists like semaglutide and tirzepatide, while also endorsing Clenbuterol and T3 for body composition.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video promotes a stack of fat-loss peptides including AOD-9604, CJC-1295, and Ipamorelin alongside GLP-1 receptor agonists like semaglutide and tirzepatide, while also endorsing Clenbuterol and T3 for body composition. Several of these compounds carry meaningful cardiovascular and endocrine risks, and none of the peptides mentioned have FDA approval for fat loss in healthy adults. The suggestion that semaglutide or tirzepatide address erectile dysfunction reflects a mischaracterization of their approved indications and mechanism of action.
- AOD-9604 completed a Phase IIb trial (Ng et al., 2000, Obesity Research) but failed to advance through Phase III and has no FDA approval for fat loss in any population.
- CJC-1295 does have clinical evidence for raising IGF-1 levels in adults (Jetté et al., 2006, Growth Hormone and IGF Research), but elevated IGF-1 does not equal proven fat loss in healthy people.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- AOD-9604 completed a Phase IIb trial (Ng et al., 2000, Obesity Research) but failed to advance through Phase III and has no FDA approval for fat loss in any population.
- CJC-1295 does have clinical evidence for raising IGF-1 levels in adults (Jetté et al., 2006, Growth Hormone and IGF Research), but elevated IGF-1 does not equal proven fat loss in healthy people.
- Clenbuterol is not FDA-approved for human use and carries documented cardiovascular risks including arrhythmia; it is not a casual fitness supplement.
- Semaglutide and tirzepatide are GLP-1-based medications approved for type 2 diabetes and obesity, not erectile dysfunction; recommending them for ED without clinical context is inaccurate.
- A 2018 analysis (Cohen et al., Drug Testing and Analysis) found a high rate of mislabeling and contamination in research compounds sold online, making DM-purchased peptides a genuine safety risk.
- Peptide compounds sold outside regulated pharmacy channels have no guaranteed purity or sterility standards, which is a separate and serious risk from their pharmacological profiles.
- Legitimate interest in peptide therapy exists, but the appropriate path involves a licensed provider, a valid prescription, and an accredited compounding pharmacy, not a social media DM.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @anthonypacellaa actually say?
The creator argued that steroids are the wrong tool for fat loss, and that peptides are "the new but really truly proven thing." He compared peptides to crypto, except better, because they have studies behind them. He also pitched T3 and Clenbuterol as legitimate shredding tools and offered AOD-9604, CJC-1295, Ipamorelin, and what sounds like Mots-C directly via DM, alongside semaglutide and tirzepatide for people with ED concerns. That last part is worth flagging immediately: semaglutide is not an erectile dysfunction treatment.
He is essentially running a peptide storefront on TikTok under the cover of a disclaimer that says the video does not promote drug use. Selling unregulated peptide compounds via social media DM is not a gray area. It is a regulatory problem regardless of what the caption says.
Does the science back this up?
Partially, and that partial part matters a lot. The claim that peptides are "actually really proven" overstates where the research currently sits, particularly for compounds like AOD-9604 and Mots-C in healthy adults seeking fat loss.
AOD-9604 is a modified fragment of human growth hormone. Early clinical trials showed some promise: a 2001 study by Heffernan et al. published in the Journal of Endocrinology found fat-reducing effects in obese rodents, and a Phase IIb trial by Ng et al. (2000, Obesity Research) showed modest results in obese humans. However, a Phase III trial was discontinued, and the compound has not achieved FDA approval for any indication. CJC-1295 combined with Ipamorelin does have plausible mechanistic support as a GHRH/GHRP stack stimulating growth hormone pulses. A 2006 study by Jetté et al. in Growth Hormone and IGF Research confirmed CJC-1295 elevated IGF-1 in healthy adults. That is real data. But "elevated IGF-1 in adults" is not the same as "clinically proven fat loss tool."
What did they get wrong (or right)?
He got one thing right: relying on anabolic steroids as a primary fat loss mechanism is a poor strategy for most people. Steroids do not have meaningful direct lipolytic effects; the body recomposition people attribute to them is largely driven by increased lean mass and the metabolic consequences that follow. That is a fair, if simplified, point.
What he got wrong is more significant. Calling semaglutide and tirzepatide solutions for ED is flatly inaccurate. Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist studied extensively for type 2 diabetes and obesity. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist. Neither is indicated for erectile dysfunction. There is some emerging observational data suggesting weight loss may improve erectile function secondarily, but recommending these drugs for ED without that context is misleading and potentially dangerous. Clenbuterol is not approved for human use in the United States and carries documented cardiovascular risks including tachycardia and arrhythmias (Spann and Winter, 1995, Journal of Analytical Toxicology). Presenting it casually as a shredding option is irresponsible.
What should you actually know?
The peptide market is real, the interest is legitimate, and some compounds have meaningful clinical data. But "we're seeing great studies" is doing a lot of work in this video. The studies that exist are often small, short-term, conducted in obese populations with specific metabolic dysfunction, or never completed Phase III trials. That gap between early-stage research and mainstream fitness use is enormous.
Buying peptides through a social media DM introduces a separate and serious problem: quality control. Peptides sold outside of regulated pharmacy channels have no guaranteed purity, concentration, or sterility standards. A 2018 analysis by Cohen et al. published in Drug Testing and Analysis found that a significant percentage of research compounds purchased online were either mislabeled or contaminated. If you are interested in peptide therapy, a regulated telehealth provider can assess whether you are an appropriate candidate, order compounds through accredited compounding pharmacies, and monitor your response. That is a different thing entirely from buying "Mott C" via Instagram DM from someone with 8,000 TikTok views.
The bottom line on this video
The creator has surface-level knowledge about some of these compounds and one genuinely correct point about steroid pharmacology. But the video functions as an advertisement, not education. Recommending GLP-1 drugs for ED, casually endorsing Clenbuterol, and selling unverified compounds through DMs are not minor quibbles. They are the kind of claims that get people hurt.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Anthony Pacella · TikTok creator
8.3K views on this video
Research purposes only DM for more info. This tik tok does not promote drug use of any kind. #gains#weightloss#gear#fitness
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about aod-9604 completed a phase iib trial (ng et al., 2000,?
AOD-9604 completed a Phase IIb trial (Ng et al., 2000, Obesity Research) but failed to advance through Phase III and has no FDA approval for fat loss in any population.
What does the video say about cjc-1295 does have clinical evidence for raising igf-1 levels in?
CJC-1295 does have clinical evidence for raising IGF-1 levels in adults (Jetté et al., 2006, Growth Hormone and IGF Research), but elevated IGF-1 does not equal proven fat loss in healthy people.
What does the video say about clenbuterol?
Clenbuterol is not FDA-approved for human use and carries documented cardiovascular risks including arrhythmia; it is not a casual fitness supplement.
What does the video say about semaglutide?
Semaglutide and tirzepatide are GLP-1-based medications approved for type 2 diabetes and obesity, not erectile dysfunction; recommending them for ED without clinical context is inaccurate.
What does the video say about a 2018 analysis (cohen et al., drug testing?
A 2018 analysis (Cohen et al., Drug Testing and Analysis) found a high rate of mislabeling and contamination in research compounds sold online, making DM-purchased peptides a genuine safety risk.
What does the video say about peptide compounds sold outside regulated pharmacy channels have no guaranteed?
Peptide compounds sold outside regulated pharmacy channels have no guaranteed purity or sterility standards, which is a separate and serious risk from their pharmacological profiles.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Anthony Pacella, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.